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complications treatment costs were the main cost driver, accounting for 67% and
77% of total direct costs of the insulin detemir therapy and NPH insulin therapy
respectively. Due to a better reduction from baseline of HbA1c the development and
progression of complications was delayed, and the cumulative incidence of diabe-
tes complications decreased for insulin detemir plus OADs therapy versus NPH
insulin plus OADs therapy. CONCLUSIONS: The results of this study demonstrate
that insulin detemir is a very cost-effective option for the treatment of type 2
diabetes compared to NPH insulin in Portugal.
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OBJECTIVES: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in
Europe and the USA. Angiotensin-converting enzyme (ACE) inhibitors slow down
the progression of renal disease and therefore provide a renal-protective effect.
The aim of our study was to assess the most cost-effective time to start an ACE
inhibitor (or an angiotensin II receptor blocker (ARB) if coughing as a side effect
occurs) in patients with newly diagnosed type 2 diabetes in the The Netherlands.
METHODS: Three strategies were compared: treating all patients at the time of
diagnosing type 2 diabetes, screening for microalbuminuria, and screening for
macroalbuminuria. A lifetime Markov decision model with simulated 50-year-old
patients with newly diagnosed diabetes mellitus was developed using published
data on costs and health outcomes and simulating the progression of renal disease.
A health insurance perspective was adopted. RESULTS: In the base-case analysis,
the treat-all strategy is associated with the lowest costs and highest benefit and
therefore dominates screening both for macroalbuminuria and microalbuminuria.
A multivariate sensitivity analysis shows that the probability of savings is 70%.
Treating all patients with an ARB would also be a dominant strategy despite the
fact that ARBs are a much more expensive alternative. CONCLUSIONS: Patients
with type 2 diabetes should receive an ACE inhibitor immediately after diagnosis if
they do not have contraindications. An ARB should be considered for those patients
developing a dry cough under ACE inhibitor therapy. The potential for cost savings
would be even larger if the prevention of cardiovascular events were considered.
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OBJECTIVES: The UK Prospective Diabetes Study (UKPDS) reported a persistence in
risk reduction of diabetes-related events associated with improved glycaemic con-
trol observed between intensive and conventional therapy groups beyond the in-
tervention period. This has important implications for projecting short-term clin-
ical trial results over long-term time horizons. The aim of this study was to
reproduce the UKPDS legacy effect and assess the impact on long-term
cost-effectiveness. METHODS: The Cardiff Type 2 Diabetes Model was initiated
with cohort profiles consistent with reported intensive versus conventional control
groups within UKPDS; initial HbA1c treatment effects were applied and modelled
over time assuming two scenarios: a loss of antihyperglycaemia benefit at year 10
or maintenance of clinical benefit (the legacy effect). Under both scenarios, risk
reductions and cost-effectiveness of sulphonylurea (SU) versus insulin were as-
sessed over a 40-year time horizon using UK 2010 costs. Both costs and health
benefits were discounted at 3.5%. RESULTS: The risk ratio (RR) of any diabetes-
related end point predicted by the model was consistent with that reported by
UKPDS when incorporating the legacy effect (RR of 0.90 versus 0.91 in the model
and UKPDS, respectively). Ignoring the legacy effect resulted in a RR of 0.99 at year
30 and a cost per quality-adjusted life-year (QALY) of £162,400, compared with
£22,565 when including the legacy effect. CONCLUSIONS: The legacy effect of in-
tensive glucose-lowering strategies has important implications when assessing
the cost-effectiveness of new therapies. Failure to include such a legacy effect, as
seen in UKPDS, may result in new therapies for managing glycaemic control ap-
pearing less cost-effective than they actually are.
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OBJECTIVES: To estimate short-term cost-effectiveness of insulin detemir versus
Neutral Protamine Hagedorn (NPH) insulin based on incidence of self-treated hy-
poglycaemia and body-weight gain in insulin-naïve subjects with type 2 diabetes in
Sweden. METHODS: A short-term (one year) cost-effectiveness model was devel-
oped in Microsoft Excel® 2003. Hypoglycaemia incidence rates were based on
UKHSG data. Relative risk (RR) of hypoglycaemia, weight change and insulin doses
were obtained from randomized clinical trial data. Resource use (health care con-
tacts, blood glucose tests) and sick-leave following hypoglycaemia were estimated
from survey data. Effectiveness was expressed as quality adjusted life-years
(QALYs). Direct and indirect costs were in Swedish Kronor (SEK 1  €0.10, 2010
values) with unit costs from official sources. Probabilistic sensitivity analyses were
performed. RESULTS: Treatment with detemir was associated with fewer self-
treated hypoglycaemic events compared with NPH (RR: 0.47 [CI 0.25:0.88]) and
lower weight gain (mean difference -0.91 kg [CI -1.53;-0.28]), leading to an average
gain of 0.011 QALYs per year. Annual costs were SEK6,505 for detemir versus
SEK5,008 for NPH with an incremental cost-effectiveness ratio (ICER) of SEK139,665
per QALY gained for detemir versus NPH from a societal perspective. From a health
care perspective, annual costs were SEK5,809 for detemir and SEK3,527 for NPH
with an ICER of SEK212,909 per QALY gained for detemir versus NPH.
CONCLUSIONS: Insulin detemir can be considered cost-effective versus NPH insu-
lin in insulin-naïve subjects with type 2 diabetes in Sweden already in the first year
of treatment, both from a health care and a societal perspective, based on reduc-
tions in self-treated hypoglycemia and superior weight management. Given the
non-significant differences in HbA1c control, results of the short-term analyses is
not expected to deviate substantially if longer time horizons are applied. Higher
pharmacy costs with insulin detemir should not be a barrier to therapy based on
these findings.
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OBJECTIVES: This analysis of CHOICE presents resource use data from the six
months pre and post initiation of adult patients’ first injectable therapy for the
treatment of T2D (ExBID or INS). CHOICE is an ongoing European 6 country pro-
spective observational study. METHODS: Patient data are collected immediately
before (baseline), and 3, 6, 12, 18 and 24 months after, initiation of injectable
therapy. RESULTS: Important baseline differences between the ExBID and INS co-
horts prevent direct comparison of outcome data. In the ExBID cohort (baseline
n1177; 6 months n1073) 78.8% patients self-monitored their blood glucose
(SMBG) at baseline; 81.6% at 6 months. Mean (SD) tests/week (past 4 weeks) were
9.28 (7.93) and 8.24 (6.41) respectively. Mean (SD) number of oral antihyperglycae-
mic medications used was 1.20 (0.75) at baseline and 1.42 (0.73) at 6 months. 93.4%
patients had 1 contact with a health care professional (HCP) in 6 months before
ExBID initiation (mean [SD] 7.75 [7.49] visits); 89.1% in 6 months post initiation (7.55
[7.41]). In the INS cohort (baseline n1315; 6 months n1235), 79.8% patients SMBG
at baseline; 92.4% at 6 months. Mean (SD) tests/week were 9.91 (8.58) and 13.08
(8.46) respectively. Mean (SD) number of oral antihyperglycaemic medications used
was 0.96 (0.76) at baseline and 0.98 (0.77) at 6 months. 93.8% patients had1 contact
with a HCP in 6 months before INS initiation (mean [SD] 8.45 [9.19] visits); 93.2% in
6 months post initiation (11.11 [16.75]). Mean doses of both ExBID and INS increased
during the first 6 months post initiation. In both ExBID and INS cohorts, between-
country variability was found. CONCLUSIONS:Mean resource utilisation increased
following initiation of injectable therapy. Increases in mean test strip use/week
(32%) and mean number of contacts with HCPs (31%) were observed in the INS
cohort. Respective observations for ExBID cohort were -12.7% and -2.7%.
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OBJECTIVES: Hypercortisolism in Cushing’s Disease (CD) is associated with signif-
icant comorbidities, which improve and in some cases are reversed with biochem-
ical control (BC). The purpose of this study was to capture data describing comor-
bidity reductions with BC and estimate the potential cost savings associated with
reversal. METHODS: Comorbidity reductions with BC were identified through a
comprehensive literature search using CD AND epidemiology, morbidity, compli-
cations, BC and treatment outcomes as search terms. Selected clinical studies
detailed the relationship between comorbidity and BC in adults. In the cost analy-
sis, comorbidities were selected if reported in patients achieving BC. Literature-
based cost estimates were identified for CD-related comorbidities from the US
payer perspective, and inflated to 2010 USD. Cost ranges were reported as the
difference between expected comorbidity costs in uncontrolled and controlled pa-
tients. Sensitivity analyses were conducted to also include possibly reversible
comorbidities. RESULTS: Patients with CD experience comorbidities ranging from
back pain (86%) to psychosis (1.4%). Of 16 comorbidities identified in this study,
seven were certainly reversible in CD patients achieving BC. Hypertension and
diabetes mellitus were reversed in 44% and 40% of patients achieving BC at 1 year.
Psychiatric illness and nephrolithiasis were resolved in 76% and 50% of CD pa-
tients. In CD patients with reported impaired glucose tolerance and overweight/
obesity, 60% and 37% of cases were resolved with BC. The application of cost esti-
mates to prevalence of each reversible comorbidity before BC yielded a total per-
patient cost of $19,239-$27,600. With BC, expected comorbidity costs ranged from
$12,448-$18,312, representing a cost savings of $6,790-$9,288. Sensitivity analysis
including possibly reversible comorbidities (like back pain, osteoporosis and ver-
tebral fractures) produced estimated total cost savings of $10,571-$14,806 (incre-
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mental cost savings, $3,780-$5,518). CONCLUSIONS: Comorbidity improvement
and resolution in CD can be achieved with BC, which confers a commensurate cost
savings to the health care payer.
Diabetes/Endocrine Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: Non-adherence to insulin therapy in patients with type 2 diabetes
presents a serious challenge. Potential explanations for non adherence may in-
clude aversion to insulin self-injection and fear of hypoglycemic events. In clinical
trails, insulin analogs have shown to reduce the risk of hypoglycemic events versus
human insulins, and a recent review suggests that insulin delivered via a pen
device may result in greater adherence versus vial and syringe. This study was
conducted to compare the adherence rates of patients initiating basal insulin ther-
apy with insulin detemir (IDet) FlexPen® versus those initiating basal insulin ther-
apy with NPH via vial and syringe. METHODS: Data were gathered from a large US
national payer retrospective claims database, and included only patients with type
2 diabetes that initiated basal insulin therapy with either IDet FlexPen® or NPH in
vials. Patients with claims for any other type of insulin, other than the index insulin
formulations during the 12-month observation period were excluded. Patients
were defined as being adherent to therapy if they had a medication possession
ration (MPR) of at least 0.80 in the 12-month follow up period. RESULTS: The IDet
FlexPen® cohort (n1082) and the NPH vial cohort (n794) were of similar age
(54.06 vs. 53.13, p0.134); however, the IDet FlexPen® cohort had a lower propor-
tion of female patients (44% vs. 55%, p0.001) and fewer patients without a history
of pre-index OADs (9% vs 45%, p0.001), than the NPH vial cohort. After controlling
for important confounders, patients initiating insulin therapy with IDet FlexPen®
were 39% more likely to achieve an MPR of 0.80 or greater versus patients initiating
insulin therapy with NPH vial (95% CI: 1.04-1.85). CONCLUSIONS: These results
suggest that adherence may be improved for patients initiating basal insulin ther-
apy with IDet in the FlexPen® versus NPH in a vial.
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OBJECTIVES: To identify studies examining adherence with oral diabetes mellitus
(DM) medication and the potential association between adherence rates and gly-
cemic control among Brazilian patients. METHODS: A systematic literature search
was performed by two independent reviewers using MEDLINE via Pubmed and
LILACS databases (until May 2011) without limits for time or language. Specific
filters to identify studies assessing Brazilian population were not used in the search
strategy and this assessment was conducted by reviewers. Publications were in-
cluded only if adequate documentation of adherence and population could be
abstracted (adherence outcomes, thresholds used, and characteristics of the
populations). RESULTS: The search strategy identified 289 records (Pubmed174
and LILACS115), from which only 2 cross-sectional studies met the eligibility
criteria and were included in the systematic review. The most recent study (Araujo
2010) was conducted in 2007 and evaluated 79 DM patients using the 4-item
Morisky-Green Test. Gimenes 2006 (n31) was designed to investigate if DM pa-
tients have proper knowledge of their prescription and assessed adherence
through self-reported patient compliance with medication schedule. Araujo 2010
found that 54.4% of DM patients were considered non-compliant according to the
Morisky-Green Test. Taking medication in the wrong schedule and skipping doses
were referred by 54.5% and 34% of patients, respectively. Gimenes 2006 observed
that 48.4% of patients reported taking medication in the wrong schedule and 71% of
them were classified as having unsatisfactory knowledge about their prescription.
Studies examining the association between adherence and glycemic control were
not found. CONCLUSIONS: This review reinforced the lack of adherence data for
Brazilian DM population, but the included studies confirmed that a significant
group of DM patients were poor compliers with treatment, although their findings
should be interpreted with some concerning given the small sample size and ex-
planatory nature.
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OBJECTIVES: To evaluate the patient’s adherence to diabetic medications and the
association between medication adherence and diabetic control outcome.
METHODS: A cross-sectional, investigational study using a convenient sampling
method for data collection was employed. A cohort of 540 diabetic patients attend-
ing diabetes clinic of Hospital Pulau Pinang, Malaysia was identified. A previously
validated Malaysian version of Morisky Medication Adherence Scale (MMAS) was
used for the assessment of medication adherence. Medical records were reviewed
for Hemoglobin A1C (HbA1C) levels and other diabetes related information.
RESULTS: Only 505 patients were included in the final analysis. The mean age of
the patients was 58.16 years (SD9.16), with 50.7% males and the mean diabetes
duration was 9.68 years (SD6.31). The mean MMAS scores was 6.11 (SD 1.66) in
which 42.2% were low, 36.4% were medium and only 21.4% were in high adherence
group and the mean HbA1C was 7.94 (SD1.61). Significant association between
medication adherence and different educational level, diabetes duration, medica-
tion number, self monitoring of blood glucose and glycemic control was found.
Higher MMAS score was found in patients with lower HbA1c levels, less number of
medications per day, longer diabetes duration, with self monitoring of blood glu-
cose and higher level of education. MMAS scores correlates significantly with
HbA1c (- 0.505, p 0.001).CONCLUSIONS:The lower HbA1C results in patients with
higher medication adherence can be the result of other factors but this study re-
vealed that adherence is among the modifiable factors that are associated with
better glycemic control. The study results reinforce the recommendation for the
periodic assessment of medication adherence and the use of educational programs
to improve the self-management ability of patients and enhance patients’ aware-
ness about glycemic control with diabetes.
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OBJECTIVES: To describe the clinical and health-related quality of life (HRQoL)
impact of patient-reported mild hypoglycaemic episodes and quantify the extent
of physician-reported agreement with patient-reported mild hypoglycaemic epi-
sodes in patients with type 2 diabetes mellitus (T2DM). METHODS: We have used
data from the Adelphi Diabetes VII (2010) Disease Specific Programme (DSP) which
collected data from 379 Primary Care physicians (PCPs) across 5 EU countries -
France, Germany, Italy, Spain and UK- for patients receiving at least one oral anti-
diabetic with or without insulin. This generated 1145 physician-completed patient
record forms (PRFs) that could be matched directly to patient-completed question-
naires (PSCs). Patients were asked: “How often do you have mild low blood sugar
experiences (those you have treated by eating some fruit, fruit juice or a sweet)”,
while physicians were asked to capture “How often does the patient experience
mild (self treated) hypoglycaemic episodes”? RESULTS: 88 patients out of 1093
(8.05%) reported hypoglycaemic episodes, whereas physicians reported that only
39 patients (3.57%) suffered hypoglycaemic episodes. Physician and patient did not
agree in 55 cases. The Fisher’s test suggests that the physician-reported prevalence
of hypoglycaemic episodes was not influenced by whether or not the patient com-
pleted a PSC (p0.374). Multivariate regression analysis including age, gender, BMI,
and duration of T2DM as covariates shows that the utility decrement (HRQoL) is
-0.0687 (p0.01) between the patients who had experienced hypoglycaemic epi-
sodes and those who had not. Patients who reported hypoglycaemic episodes also
had a significantly higher HbA1c 0.374 (p0.01) than those who did not report
hypoglycaemia. CONCLUSIONS: PCPs in Europe may underestimate the true inci-
dence rate of mild hypoglycaemia as their treated patients report over twice as
many as they do. The occurrence of patient-reported hypoglycaemic episodes is
associated with lower HRQoL and significantly higher HbA1c and hence has sub-
stantial clinical impact.
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OBJECTIVES: This study aimed to translate the Michigan Diabetes Knowledge Test
(MDKT) into Pakistani (Urdu) language, and to examine the psychometric proper-
ties of the Urdu version. METHODS: A standard procedure of “forward-backward”
translation procedure was used to create the Urdu version of the MDKT from the
original English version. A convenience sample of 325 outpatients with type 2
diabetes was approached between June and November 2010. All data were col-
lected from Bolan Medical College Hospital, Quetta, Pakistan. In addition to MDKT,
socio-demographic data of the patients was also collected. Patient medical records
were explored to get clinical and hemoglobin A1c data. For the purpose of test-rest
analysis, Spearman’s rho coefficient was used and data was available from 51
patients. Internal consistency was used as a measurement of reliability using Cron-
bach’s alpha. Known group validity was also measured to ensure the consistency of
the MDKT. RESULTS: By using the recommended scoring methods of MDKT, the
mean SD of MDKT scores was reported as 7.562.98. Cronbach’s alpha value was
0.702 showing good internal consistency. Test-retest reliability value was 0.812 (p
0.001). Significant relationship between MDKT categories and HbA1c categories
(chi-square  20.555; p  0.001) was found for known group validity.
CONCLUSIONS: The findings of this validation study reveal that that the Pakistani
(Urdu) version of the MDKT is a reliable and valid measure of diabetes knowledge
that can be used in clinical and research practice of Pakistani health care system.
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